H-F Petereit

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi [DRGs as future reimbursement system for hospital services exemplified by multiple sclerosis]
    H F Petereit
    Klinik fur Neurologie, Klinikum der Universität zu Köln, Josef Stelzmann Strasse 9, 50924 Köln
    Nervenarzt 73:785-91. 2002
  2. ncbi Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients
    H F Petereit
    Department of Neurology and Psychiatry, University of Cologne, Cologne 50924, Germany
    Mult Scler 8:492-4. 2002
  3. ncbi Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis
    H F Petereit
    Department of Neurology and Psychiatry, University of Cologne, Josef Stelzmann Str 9, D 50924 Cologne, Germany
    J Neurol Sci 206:209-14. 2003
  4. ncbi Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor
    H F Petereit
    Department of Neurology, University of Cologne, D 50924 Cologne, Germany
    Mult Scler 9:16-20. 2003
  5. ncbi No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis
    H F Petereit
    Department of Neurology and Psychiatry, University of Cologne, Josef Stelzmann Str 9, 50924 Kö1n, Germany
    Mult Scler 12:66-71. 2006
  6. ncbi [Detecting infectious agents in central nervous system inflammation by cerebrospinal fluid analysis]
    H F Petereit
    Klinik und Poliklinik fur Neurologie, Klinikum der Universität zu Köln
    Nervenarzt 77:481-92; quiz 493-4. 2006
  7. ncbi The immunomodulatory properties of in vitro immunoglobulins are dose-dependent
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 108:267-73. 2003
  8. ncbi Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system--value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 112:207-13. 2005
  9. ncbi Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease
    B Bosche
    Department of Neurology, University of Cologne, Germany
    Acta Neurol Scand 113:433-6. 2006
  10. ncbi Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 109:66-70. 2004

Collaborators

Detail Information

Publications17

  1. ncbi [DRGs as future reimbursement system for hospital services exemplified by multiple sclerosis]
    H F Petereit
    Klinik fur Neurologie, Klinikum der Universität zu Köln, Josef Stelzmann Strasse 9, 50924 Köln
    Nervenarzt 73:785-91. 2002
    ..The possible role of the DRG system as a cost- and quality-controlling tool in the German public health system as well as its potential risks in the absence of broadly accepted treatment guidelines is discussed...
  2. ncbi Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients
    H F Petereit
    Department of Neurology and Psychiatry, University of Cologne, Cologne 50924, Germany
    Mult Scler 8:492-4. 2002
    ..6%. These preliminary results encourage further evaluation of IFG as predictor of an IFNB treatment response...
  3. ncbi Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis
    H F Petereit
    Department of Neurology and Psychiatry, University of Cologne, Josef Stelzmann Str 9, D 50924 Cologne, Germany
    J Neurol Sci 206:209-14. 2003
    ..009) and lower T2 lesion load (p=0.03). Interleukin-10 might not only play a role in the pathological process of multiple sclerosis but has an impact on disease outcome as well...
  4. ncbi Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor
    H F Petereit
    Department of Neurology, University of Cologne, D 50924 Cologne, Germany
    Mult Scler 9:16-20. 2003
    ..001). These in vitro findings might indicate that Igs in high doses potentially interfere with neuroprotective mechanisms despite their potent anti-inflammatory properties...
  5. ncbi No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis
    H F Petereit
    Department of Neurology and Psychiatry, University of Cologne, Josef Stelzmann Str 9, 50924 Kö1n, Germany
    Mult Scler 12:66-71. 2006
    ..Against our expectations, IVIG did not reduce the relapse rate or the progression of disability or cytokine production. Our data argue against an enduring immunomodulating effect of IVIG, at least in SPMS...
  6. ncbi [Detecting infectious agents in central nervous system inflammation by cerebrospinal fluid analysis]
    H F Petereit
    Klinik und Poliklinik fur Neurologie, Klinikum der Universität zu Köln
    Nervenarzt 77:481-92; quiz 493-4. 2006
    ..The following text gives an overview of appropriate detection methods and their relevance to the most important CNS infections...
  7. ncbi The immunomodulatory properties of in vitro immunoglobulins are dose-dependent
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 108:267-73. 2003
    ..CONCLUSION: Besides a suppression of the pro-inflammatory cytokines IFN-gamma and TNF, IgG enhances the anti-inflammatory cytokine IL-10. This effect is dose-dependent, speaking in favour of higher IgG doses in the treatment of MS...
  8. ncbi Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system--value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 112:207-13. 2005
    ..g. multiple sclerosis (MS). Because of different treatment strategies, it is important to distinguish between these different autoimmune diseases...
  9. ncbi Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease
    B Bosche
    Department of Neurology, University of Cologne, Germany
    Acta Neurol Scand 113:433-6. 2006
    ..CONCLUSION: The authors suggest that all diagnostic multiple sclerosis criteria including typical CSF findings should be ascertained before INF-beta treatment is initiated...
  10. ncbi Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 109:66-70. 2004
    ..CONCLUSION: Our data indicate that IFNB therapy may induce long-term NAB production which persists even after discontinuating IFNB treatment. Possible immunological mechanisms are discussed...
  11. ncbi [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters]
    D Reske
    Klinik und Poliklinik fur Neurologie, Klinikum der Universität zu Köln, Koln
    Nervenarzt 75:945-52. 2004
    ....
  12. ncbi Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus?
    J Brettschneider
    Department of Neurology, University of Ulm, Germany
    J Neurol Neurosurg Psychiatry 75:1614-6. 2004
    ..Because dementia is associated with neuronal loss, we investigated whether leptomeningeal dysfunction may be involved in the pathogenesis of dementia disorders...
  13. ncbi Gender change and its impact on the course of multiple sclerosis
    D Reske
    Department of Neurology, University of Cologne, Cologne, Germany
    Acta Neurol Scand 113:347-9. 2006
    ..As there are several studies investigating an immunomodulatory impact of hormones on the course of MS or experimental allergic encephalomyelitis, we discuss the presented case and a possible influence of androgens in this patient...
  14. ncbi Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis
    H F Petereit
    Department of Neurology, University of Colgne, D 50824 Cologne, Germany
    Acta Neurol Scand 117:399-403. 2008
    ....
  15. ncbi [Complications and diagnostic limitations of chronic meningitis]
    N Galldiks
    Klinik und Poliklinik für Neurologie der Universität zu Köln
    Dtsch Med Wochenschr 130:1633-6. 2005
    ..Additionally, she complained about fatigue, headache, chills, fever, muscle pain and neck stiffness since 4 days. At admission, the body temperature was 38.7 degrees C. Neurological examination revealed papilledema and meningism...
  16. ncbi Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate
    S Nolden
    Department of Neurology, University of Cologne, 50924 Cologne, Germany
    Mult Scler 11:245-8. 2005
    ..A T-cell pseudolymphoma is a very rare side effect of GLAT treatment. For clinical purposes it is important to state that re-exposition after GLAT-induced pseudolymphoma is possible without permanent sequelae...
  17. ncbi Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica
    S Jarius
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany
    J Neurol Neurosurg Psychiatry 79:1134-6. 2008
    ....